CABA earnings analysis
What we found in CABA's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Cabaletta's Q2 2026 EPS loss improved to -$0.34 from -$0.73 a year earlier, and $225.1 million of cash is expected to fund operations into mid-2027. However, six-month net loss increased to $94.5 million from $81.1 million, the filing newly identifies substantial doubt about the company's ability to continue as a going concern, and additional financing is required. Clinical progress in myositis is encouraging, but manufacturing dependence, external-control regulatory uncertainty, dilution and near-term funding risks remain significant.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Quarterly EPS Loss Narrowed
- Q2 2026 diluted EPS was -$0.34, improving from -$0.39 in Q1 2026 and -$0.73 in Q2 2025. The year-over-year loss narrowed by $0.39 per share.
- Cash Runway Extends Into Mid-2027
- Cash and cash equivalents were $225.1 million at June 30, 2026. Management expects this balance to fund operations into mid-2027.
- Clinical Investment Increased Losses
- Six-month net loss increased to $94.5 million from $81.1 million in the prior-year period, a $13.4 million or 16.5% increase, reflecting continued investment in clinical development.
- Capital Raised to Fund Development
- The company raised approximately $140.2 million of net proceeds from a May 2026 equity offering and an additional $28.7 million through its ATM program during the six months ended June 30, 2026.
- Myositis Endpoint Performance Positive
- Management reported 80% registrational-endpoint performance, or 8 of 10 evaluable adult myositis patients, supporting continued advancement of the rese-cel program.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Going-Concern Risk Newly Identified
- The company explicitly states that substantial doubt exists about its ability to continue as a going concern for at least 12 months following the filing. Although cash was $225.1 million and is expected to fund operations into mid-2027, management says substantial additional financing will be required.
- Further Equity Dilution Risk
- Equity financing has created substantial dilution: the May 2026 offering issued 51,725,000 shares for approximately $140.2 million of net proceeds, while the ATM program issued 10,132,367 shares for $28.7 million during the first six months of 2026.
- Near-Term Warrant Financing Uncertain
- As of June 30, 2026, 47,815,090 common-stock warrants remained outstanding, with an exercise price of $2.50 per share and expiration on September 12, 2026. If exercised for cash, the company could receive approximately $120.0 million, but unexercised warrants would provide no proceeds.
- Lonza Manufacturing Dependency Updated
- The company is reliant on Lonza for current manufacturing activities. The Lonza Agreement has an initial five-year term, but Lonza may terminate with written notice subject to a three-month ramp-down period, potentially disrupting clinical supply and commercial-readiness plans.
- External-Control Regulatory Risk
- FDA feedback in March 2026 identified potential baseline differences between the RESET-Myositis trial and its proposed registry external control, including diagnosis classification and refractory definitions, as well as missing data. The planned registrational study uses a 16-week primary endpoint, so an unsuitable external control could require additional data or a randomized trial.
- Limited Target Engagement Risk
- CAAR T candidates target approximately 0.01% to 1% of a patient's B cells, creating a risk that insufficient target engagement will prevent adequate engraftment and elimination of pathogenic B cells. This could delay development or require product and manufacturing changes.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.34
What they said about what is next.
No quantitative revenue or EPS guidance was provided. Management expects cash and cash equivalents of $225.1 million as of June 30, 2026 to fund operations into mid-2027, but states that substantial additional financing will be required and that substantial doubt exists about continuing as a going concern for at least 12 months following the filing.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 14, 2026
- Cabaletta Bio, Inc. (CABA) reported a net loss of $43.5 million in Q1 2026 with an EPS of -0.39, outperforming analyst expectations of -0.71 by 45.2%. Notably, the cash position decreased from $133.6 million at the end…
- 10-K · March 23, 2026
- Cabaletta (CABA) is a late clinical‑stage biotech focused on its CABA® CARTA platform and lead product rese-cel, pursuing registrational cohorts across multiple autoimmune indications. The 2025 filing highlights…
- 10-K · March 31, 2025
- Cabaletta remains a clinical-stage CAR T company focused on its CABA® platform and lead candidate rese-cel, with multiple IND clearances and early clinical signals across autoimmune indications. The company reports…
- 10-Q · November 14, 2024
- Cabaletta reported a wider quarterly loss as R&D investment accelerated; GAAP net loss for the three months ended September 30, 2024 was $30,629 (EPS $0.62 loss) versus $16,448 (EPS $0.37 loss) in the prior-year…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing CABA makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever